Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-646-6773875
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees30
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions
What is Actinium Pharmaceuticals' stock symbol?
Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."
How were Actinium Pharmaceuticals' earnings last quarter?
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) released its quarterly earnings results on Tuesday, March, 19th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.06). View Actinium Pharmaceuticals' Earnings History.
When is Actinium Pharmaceuticals' next earnings date?
What price target have analysts set for ATNM?
4 analysts have issued 12-month target prices for Actinium Pharmaceuticals' shares. Their predictions range from $3.00 to $6.00. On average, they anticipate Actinium Pharmaceuticals' share price to reach $4.25 in the next twelve months. This suggests a possible upside of 1,641.8% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals.
What is the consensus analysts' recommendation for Actinium Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.
What are Wall Street analysts saying about Actinium Pharmaceuticals stock?
Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (6/4/2019)
- 2. Maxim Group analysts commented, "Actinium reported 4Q18 and FY18 with a net loss of ($6.4M) and ($23.7M), respectively. The company ended the year with $13.6M in cash on the balance sheet (not including $2.5M warrant exercises). The company also has a $30M ATM in place. Combined, the company should have sufficient runway to get the P3 data for Iomab in 1H20." (3/20/2019)
Has Actinium Pharmaceuticals been receiving favorable news coverage?
News coverage about ATNM stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Actinium Pharmaceuticals earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Actinium Pharmaceuticals.
Are investors shorting Actinium Pharmaceuticals?
Actinium Pharmaceuticals saw a decline in short interest in April. As of April 30th, there was short interest totalling 2,171,585 shares, a decline of 24.8% from the April 15th total of 2,888,176 shares. Based on an average daily volume of 3,600,517 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.4% of the shares of the company are sold short. View Actinium Pharmaceuticals' Current Options Chain.
Who are some of Actinium Pharmaceuticals' key competitors?
Some companies that are related to Actinium Pharmaceuticals include BioTime (BTX), CorMedix (CRMD), BioTime (BTX), Oxford Biodynamics (OBD), Ergomed (ERGO), Verseon (VSN), Cynata Therapeutics (CYP), Neuren Pharmaceuticals (NEU), Matinas Biopharma (MTNB), Matinas BioPharma (MTNB), Fennec Pharmaceuticals (FRX), Equillium (EQ), Ampliphi Biosciences (APHB), Botanix Pharmaceuticals (BOT) and Covalon Technologies (COV).
What other stocks do shareholders of Actinium Pharmaceuticals own?
Who are Actinium Pharmaceuticals' key executives?
Actinium Pharmaceuticals' management team includes the folowing people:
- Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
- Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
- Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)
- Dr. Mark S. Berger, Chief Medical Officer (Age 64)
- Mr. Anil Kapur, Chief Commercial Officer (Age 50)
Who are Actinium Pharmaceuticals' major shareholders?
Actinium Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Oppenheimer & Co. Inc. (0.15%). Company insiders that own Actinium Pharmaceuticals stock include Ajit Shetty, Dale L Ludwig, Nitya G Ray, Sandesh Seth and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals.
Which major investors are buying Actinium Pharmaceuticals stock?
ATNM stock was acquired by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc.. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Ajit Shetty, Dale L Ludwig, Nitya G Ray, Sandesh Seth and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals.
How do I buy shares of Actinium Pharmaceuticals?
Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Actinium Pharmaceuticals' stock price today?
One share of ATNM stock can currently be purchased for approximately $0.2440.
How big of a company is Actinium Pharmaceuticals?
What is Actinium Pharmaceuticals' official website?
How can I contact Actinium Pharmaceuticals?
Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.
MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
